Abstract
We analyzed the antiproliferative effect of simvastatin (SV),an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase,on human glioma cell lines. Inhibition of cellgrowth with SV was observed in all celllines tested. Different culture conditions altered this inhibitionof growth: the lower the concentration of fetalbovine serum (FBS) in the medium, the higherthe inhibitory effect of SV on glioma cells.On morphological examination, we found that most ofthe cells exposed to SV became rounded andthe proportion of floating cells was increased ina time-dependent manner. Then we examined whether exogenouslyadded mevalonic acid reversed the growth inhibitory effectof SV. Exogenous mevalonic acid suppressed the inhibitoryeffect of SV on glioma cells in adose-dependent manner. SV also enhanced the expression oflow-density lipoprotein (LDL) receptor on glioma cells. Wealso found that peroxidized LDL (p-LDL) was cytotoxicto glioma cells and that SV had additiveeffects on pLDL-induced cytotoxicity. In a mouse model,growth of glioma cells inoculated into nude micewas inhibited by intratumoral injection of both SVand peroxidized LDL. These results indicate that mevalonicacid or a metabolite in the cholesterol synthesispathway is necessary for the growth of gliomacells and that simvastatin and/or peroxidized LDL shouldbe examined further as potential therapeutic agents forgliomas.
Similar content being viewed by others
References
Langan TJ, Volpe JJ: Cell cycle-specific requirement for mevalonate, but not for cholesterol, for DNA synthesis in glial primary cultures. J Neurochem 49: 513–521, 1987
Fairbanks KP, Witte LD, Goodman DS: Relationship between mevalonate and mitogenesis in human fibroblasts stimulated with platelet-derived growth factor. J Biol Chem 259: 1546–1551, 1984
Maltese WA: 3-hydroxy-3-methylglutaryl coenzyme A reductase in human brain tumors. Neurol 33: 1294–1299, 1983
Wejde J, Blegen H, Larsson O: Requirement for mevalonate in the control of proliferation of human breast cancer cells. Anticanc Res 12: 317–324, 1992
Ho YK, Smith RG, Brown MS, Goldstein JL: Low density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood 52: 1099–1114, 1978
Vitols S, Gahrton G, Ost A, Peterson CO: Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation. Blood 63: 1186–1193, 1984
Rudling MJ, Angelin B, Peterson CO, Collins VP: Low density lipoprotein receptor activity in human intracranial tumors and its relation to the cholesterol requirement. Cancer Res 50: 483–487, 1990
Albert A, Chen J, Kuron G, Hunt V, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patshett A, Monaghann R, Currie S, Stapley E, Albers-Schonberg G, Hensen O, Hirshfield J, Hoogsteen K, Liesch J, Springer J: Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 77: 3957–3961, 1980
Hoffman W, Alberts A, Anderson P, Chen J, Smith R, Willard A: 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, 4. side chain ester derivatives of mevinolin. J Med Chem 29: 849–852, 1986
Casey P, Solski P, Der C, Buss J: p21 ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci USA 86: 8323–8327, 1989
Willumsen B, Christensen A, Hubbert N, Papageorge A, Lowy D: The p21 ras C-terminus is required for transformation and membrane association. Nature 310: 583–586, 1984
Chang E, Furth M, Scolnick E, Lowy D: Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus. Nature 297: 479–483, 1982
Stacey D, Kung H: Transformation of NIH 3T3 cells by microinjection of Ha-ras p21 protein. Nature 310: 508–511, 1984
Sumi S, Beauchamp DR, Townsend CM, Uchida T, Murakami M, Rajaraman S, Ishizuka J, Thompson JC: Inhibition of pancreatic adenocarcinoma cell growth by Lovastatin. Gastroenterology 103: 982–989, 1992
Yamazaki H, Fukui Y, Ueyama Y, Tamaoki N, Kawamoto T, Taniguchi S, Shibuya M: Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors. Mol Cell Biol 8: 1816–1820, 1988
Fossel ET, Fletcher JG, McDonagh J, Hui KKS: Selective cytotoxicity of low-density lipoprotein to helper T cells of cutaneous T-cell lymphoma after photoperoxidation with 8-methoxypsoralen. J Natl Canc Inst 83: 1316–1321, 1991
Fossel ET, Zanella CL, Fletcher JG, Hui KKS: Cell death induced by peroxidized low-density lipoprotein: endopepsis. Cancer Res 54: 1240–1248, 1994
Nagata Y, Hidaka Y, Ishida F, Kamei T: Effect of simvastatin (MK-733) on the regulation of cholesterol synthesis in Hep G2 cells. Biochem Pharmacol 40: 843–850, 1990
Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55–63, 1983
Soma MR, Pagliarini P, Butti G, Paoletti R, Paoletti P, Fumagalli R: Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N’;-bis(2-chloroethyl)-N-nitrosourea and ?-interferon on human glioma cells. Cancer Res 52: 4348–4355, 1992
Brandes A, Soesan M, Fiorentino M: Medical treatment of high grade malignant gliomas in adults: an overview. Anticancer Res 11: 1988–1992, 1991
Vickers S, Duncan CA, Chen IW, Rosegay A, Duggan DE: Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos 18: 138–145, 1990
Grossi E, Paoletti P, Paoletti R: An analysis of brain cholesterol and fatty acid biosynthesis. Arch Int Physiol Biochem 66: 564–572, 1958
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kikuchi, T., Nagata, Y. & Abe, T. In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells. J Neurooncol 34, 233–239 (1997). https://doi.org/10.1023/A:1005753523949
Issue Date:
DOI: https://doi.org/10.1023/A:1005753523949